October 12, 2022 Kinnate is the latest Raf player to trip up The company’s attempt to segment Braf-mutant cancers further isn’t going smoothly.
October 15, 2021 Treme climbs a new mountain Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
